Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Luping Z. Huang"'
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 338:932-941
L-DOPA-induced dyskinesias or abnormal involuntary movements (AIMs) are a debilitating adverse complication associated with prolonged L-DOPA administration for Parkinson's disease. Few treatments are currently available for dyskinesias. Our recent da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fe5de5f67485118c108b50ecf3e1da
https://doi.org/10.1124/jpet.111.182949
https://doi.org/10.1124/jpet.111.182949
Autor:
Luping Z. Huang, Tanuja Bordia, Xiomara A. Perez, Carla Campos, Neeraja Parameswaran, Maryka Quik
Publikováno v:
Biochemical Pharmacology. 78:677-685
There exists a remarkable diversity of neurotransmitter compounds in the striatum, a pivotal brain region in the pathology of Parkinson's disease, a movement disorder characterized by rigidity, tremor and bradykinesia. The striatal dopaminergic syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50a21a977b0942615ad2d55804295bb
https://doi.org/10.1016/j.bcp.2009.05.003
https://doi.org/10.1016/j.bcp.2009.05.003
Autor:
C. Pinzon-Guzman, H.F. Schmitt, J.-H. Son, G.S. Slaton, Ursula H. Winzer-Serhan, Luping Z. Huang
Publikováno v:
Neuroscience. 157:349-359
In adult rats, acute nicotine, the major psychoactive ingredient in tobacco smoke, stimulates the hypothalamic–pituitary–adrenal axis (HPA), resulting in activation of brain areas involved in stress and anxiety-linked behavior. However, in rat pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f63fa53486865245c6904077af3c3415
https://doi.org/10.1016/j.neuroscience.2008.09.018
https://doi.org/10.1016/j.neuroscience.2008.09.018
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 327:239-247
The development of abnormal involuntary movements (AIMs) or dyskinesias is a serious complication of L-DOPA [L-3,4-dihydroxyphenylalanine] therapy for Parkinson's disease. Our previous work had shown that intermittent nicotine dosing reduced L-DOPA-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d1e539bb2091da8e1e8f0f711dbdd8
https://doi.org/10.1124/jpet.108.140897
https://doi.org/10.1124/jpet.108.140897
Publikováno v:
Journal of Neurochemistry. 105:1861-1872
Despite a dramatic loss of nigrostriatal dopaminergic neurons in Parkinson’s disease, clinical symptoms only arise with 70–80% reduction of striatal dopamine. The mechanisms responsible for this functional compensation are currently under debate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf73577dc4bb182d98e1f5b54d4cc872
https://doi.org/10.1111/j.1471-4159.2008.05268.x
https://doi.org/10.1111/j.1471-4159.2008.05268.x
Publikováno v:
Neuroscience. 146:1854-1868
Nicotine, the major psychoactive ingredient in tobacco interacting with nicotinic acetylcholine receptors (nAChR), is believed to have neuroprotective and neurotoxic effects on the developing brain. Neurotoxicity has been attributed to activation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1a5c688924647b1700901d8ed19cbd
https://doi.org/10.1016/j.neuroscience.2007.03.008
https://doi.org/10.1016/j.neuroscience.2007.03.008
Autor:
Maryka Quik, Keon Min Park, Maya Hrachova, J. Michael McIntosh, Luping Z. Huang, Archana Mallela, Sharon R. Grady
Publikováno v:
Neuropharmacology. 63(3)
L-Dopa-induced dyskinesias are a serious side effect that develops in most Parkinson’s disease patients on dopamine replacement therapy. Few treatment options are available to manage dyskinesias; however, recent studies show that nicotine reduces t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f174d5c93f096213f14ba7f94f15eae9
https://pubmed.ncbi.nlm.nih.gov/22579614
https://pubmed.ncbi.nlm.nih.gov/22579614
A promising target for improved therapeutics in Parkinson's disease is the nicotinic acetylcholine receptor (nAChR). nAChRs are widely distributed throughout the brain, including the nigrostriatal system, and exert important modulatory effects on num
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8077ec4d62c37c1f5d32a37e3d40de47
https://europepmc.org/articles/PMC3748273/
https://europepmc.org/articles/PMC3748273/
L-dopa therapy for Parkinson's disease leads to dyskinesias or abnormal involuntary movement (AIMs) for which there are few treatment options. Our previous data showed that nicotine administration reduced L-dopa-induced AIMs in parkinsonian monkeys a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022672b0443a2c9d7983a3c0c1c7db97
https://europepmc.org/articles/PMC3133531/
https://europepmc.org/articles/PMC3133531/
Nicotine reduces dopaminergic deficits in parkinsonian animals when administered before nigrostriatal damage. Here we tested whether nicotine is also beneficial when given to rats and monkeys with pre-existing nigrostriatal damage. Rats were administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f6d9f10feb16601a526ff0d565d6f64
https://europepmc.org/articles/PMC2677631/
https://europepmc.org/articles/PMC2677631/